Amprol Plus® and Aureomycin® — veterinary medication

Overview

Source: Animal Drugs @ FDA

Proprietary name

Amprol Plus® and Aureomycin®

Active ingredient

Amprolium Chlortetracycline Ethopabate

Application type

NADA

Sponsor

Phibro Animal Health Corp.

Applications on record

1

First published

June 17, 2025

Adverse event reports

Source: openFDA VeDDRA

303

Reports mentioning this ingredient

January 28, 1987 – February 11, 2026

21

Classified serious

per reporter assessment

59

Lack of expected efficacy

resistance signal

30

Human operator exposure

needle-stick or splash

Not a risk measure. Veterinary adverse event reports are influenced by how many animals are treated, reporting practice and product age. Reports do not establish that the product caused the event, and a single report can cover an entire herd or flock. Attribution here is by active ingredient because the source dataset redacts brand names.

Attributed by active ingredient “AMPROLIUM”. Green Book ingredient names and VeDDRA ingredient names do not always agree exactly, so attribution is approximate and labelled as such.

Reported reactions

Source: openFDA VeDDRA

Clinical signs coded in the VICH VeDDRA four-level hierarchy, most frequent first.

Reaction terms reported for this ingredient, by report count.
Reaction (VeDDRA term)	Reports	Relative frequency
Appearance, Abnormal	73
Lack of efficacy (protozoa) - Coccidia	40
Death	36
Contamination, Particulate Matter	34
Accidental exposure	29
Unclassifiable adverse event	26
Potency, Low	19
Diarrhoea	14
Bloody diarrhoea	13
Product defect NOS	10
Recumbency	9
Uncoded sign	9
Product Defect, General	8
Vials, Leaking	5
Abdominal pain	5
Solution, Abnormal	5
Convulsion	4
Collapse (see also 'Cardio-vascular' and 'Systemic disorders')	4
Granules/Powder, Abnormal	4
Depression	4

Species affected

Source: openFDA VeDDRA

Cattle 90 Human 30 Goat 9 Dog 8 Chicken 7 Sheep 6 Horse 4 Turkey 3 Fish 2 Rabbit 2 Other 1 Other Deer 1

Regulatory context

New Animal Drug Application (NADA). A pioneer approval evaluated for target animal safety, therapeutic effectiveness, manufacturing controls and — for food-producing species — human food safety including residue depletion.

Extra-label use in food-producing animals is governed by the Animal Medicinal Drug Use Clarification Act of 1994 (AMDUCA) and 21 CFR Part 530. It requires a valid veterinarian-client-patient relationship and is prohibited outright for certain drug classes. Withdrawal times are determined by FARAD, not by this index.

Sources for this page

Animal Drugs @ FDA	FDA CVM	Applications, sponsor, status, withdrawal
Animal & Veterinary Events	FDA CVM	VeDDRA adverse event aggregates by active ingredient